Workflow
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
BDRXBiodexa Pharmaceuticals PLC(BDRX) Newsfilter·2024-05-22 12:30

May 22, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Biodexa Announces 7MillionofGrossProceedsfromWarrantExercisesProceedsCoverYear1eRapaPhase3Obligations,UnlockingTwicethatAmountinNon−dilutiveGrantFundingBiodexaPharmaceuticalsPLC,(Nasdaq:BDRX),anacquisition−focusedclinicalstagebiopharmaceuticalcompanydevelopingapipelineofinnovativeproductsforthetreatmentofdiseaseswithunmetmedicalneeds,announces7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces 7 million of gross proceeds from the exercis ...